KR102030447B9 - 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 - Google Patents
퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들Info
- Publication number
- KR102030447B9 KR102030447B9 KR1020137023174A KR20137023174A KR102030447B9 KR 102030447 B9 KR102030447 B9 KR 102030447B9 KR 1020137023174 A KR1020137023174 A KR 1020137023174A KR 20137023174 A KR20137023174 A KR 20137023174A KR 102030447 B9 KR102030447 B9 KR 102030447B9
- Authority
- KR
- South Korea
- Prior art keywords
- compounds
- processes
- pharmaceutical compositions
- compositions containing
- preparing quinoline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161441520P | 2011-02-10 | 2011-02-10 | |
US201161441527P | 2011-02-10 | 2011-02-10 | |
US61/441,520 | 2011-02-10 | ||
US61/441,527 | 2011-02-10 | ||
PCT/US2012/024591 WO2012109510A1 (en) | 2011-02-10 | 2012-02-10 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197012256A Division KR20190049907A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20140044782A KR20140044782A (ko) | 2014-04-15 |
KR102030447B1 KR102030447B1 (ko) | 2019-11-08 |
KR102030447B9 true KR102030447B9 (ko) | 2023-07-24 |
Family
ID=45615082
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197012256A KR20190049907A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020217002055A KR20210010671A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020137023174A KR102030447B1 (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020217038913A KR20210147117A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020207007647A KR20200031711A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020237038819A KR20230158644A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197012256A KR20190049907A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020217002055A KR20210010671A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217038913A KR20210147117A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020207007647A KR20200031711A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
KR1020237038819A KR20230158644A (ko) | 2011-02-10 | 2012-02-10 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
Country Status (21)
Country | Link |
---|---|
US (9) | US9717720B2 (ko) |
EP (2) | EP2673262B1 (ko) |
JP (2) | JP2014505109A (ko) |
KR (6) | KR20190049907A (ko) |
CN (1) | CN103459373B (ko) |
AR (1) | AR085155A1 (ko) |
AU (5) | AU2012214322B2 (ko) |
BR (1) | BR112013020362A2 (ko) |
CA (1) | CA2826751C (ko) |
DK (1) | DK2673262T3 (ko) |
EA (1) | EA033513B1 (ko) |
ES (1) | ES2905571T3 (ko) |
GE (1) | GEP20217235B (ko) |
HU (1) | HUE057574T2 (ko) |
IL (1) | IL227848B (ko) |
MX (1) | MX2013009116A (ko) |
PL (1) | PL2673262T3 (ko) |
PT (1) | PT2673262T (ko) |
TW (2) | TW201309650A (ko) |
WO (1) | WO2012109510A1 (ko) |
ZA (1) | ZA201306072B (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
ES2904646T3 (es) | 2010-07-16 | 2022-04-05 | Exelixis Inc | Composiciones farmacéuticas moduladoras de c-Met |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
TW201309650A (zh) | 2011-02-10 | 2013-03-01 | Exelixis Inc | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
UA115866C2 (uk) | 2011-09-22 | 2018-01-10 | Екселіксіс, Інк. | Спосіб лікування остеопорозу |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
NZ712330A (en) | 2013-03-15 | 2020-04-24 | Exelixis Inc | Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
CN103751140A (zh) * | 2014-01-15 | 2014-04-30 | 青岛市肿瘤医院 | 一种Cabozantinib分散片及其制备方法 |
BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
EP3119476A1 (en) | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
US20210275515A1 (en) | 2016-09-27 | 2021-09-09 | The US of America As Represented By The Secretary, Dept. of Health and Human Services | Method of Treating Urothelial Carcinoma and Other Genitourinary Malignancies Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
EP3630726B1 (en) | 2017-05-26 | 2021-12-22 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
CN111757735B (zh) | 2018-01-26 | 2023-09-22 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
CA3126721A1 (en) | 2019-01-25 | 2020-07-30 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
WO2024110606A1 (en) | 2022-11-25 | 2024-05-30 | Synthon B.V. | A process for preparation of cabozantinib or tivozanib |
CN116333534B (zh) * | 2023-04-04 | 2023-11-17 | 清远拜克家居有限公司 | 一种耐老化木质板材用水性涂料及其制备方法 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
ES2281591T3 (es) * | 1999-01-22 | 2007-10-01 | Kirin Beer Kabushiki Kaisha | Derivados de n-((quinolinil)oxil)-fenil)-urea y de n-((quinazolinil)oxil)-fenil)-urea con actividad antitumoral. |
AU2003225668A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
JP3763414B2 (ja) * | 2002-10-21 | 2006-04-05 | 麒麟麦酒株式会社 | N−{2−クロロ−4−[(6,7−ジメトキシ−4−キノリル)オキシ]フェニル}−n’−(5−メチル−3−イソキサゾリル)ウレアの塩の結晶形 |
CA2537812C (en) | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
JP4890255B2 (ja) | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
EP2567955A3 (en) | 2003-12-25 | 2013-03-27 | Eisai R&D Management Co., Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
TWI392681B (zh) | 2006-04-06 | 2013-04-11 | Daiichi Sankyo Co Ltd | 高純度普拉格雷及其酸加成鹽之製法 |
US20080004273A1 (en) | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
WO2009136663A1 (en) * | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
UY32142A (es) | 2008-09-26 | 2010-05-31 | Smithkline Beckman Corp | Preparación de una quinoliniloxidifenilciclopropanodicarboxamida |
CN102282134B (zh) | 2008-11-13 | 2015-04-01 | 埃克塞里艾克西斯公司 | 喹啉衍生物制备方法 |
TW201028383A (en) | 2008-12-04 | 2010-08-01 | Exelixis Inc | Methods of preparing quinoline derivatives |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
WO2010113183A2 (en) | 2009-04-03 | 2010-10-07 | Msn Laboratories Limited | Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts |
KR20120051702A (ko) | 2009-07-17 | 2012-05-22 | 엑셀리시스, 인코포레이티드 | N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모르폴린-4-일프로필)옥시〕퀴놀린-4-일}옥시)페닐〕-n''-(4-플루오로페닐)시클로프로판-1,1-디카르복사미드의 결정형 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2011031840A1 (en) | 2009-09-09 | 2011-03-17 | Quintiles Transnational Corp. | Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
KR20130038206A (ko) | 2010-03-12 | 2013-04-17 | 엑셀리시스, 인코포레이티드 | N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모폴린-4-일프로필)옥시〕-퀴놀린-4-일}옥시)페닐〕-n’-(4-플루오로페닐)사이클로프로판-1,1-디카복사미드의 수화된 결정형 형태 |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
ES2904646T3 (es) | 2010-07-16 | 2022-04-05 | Exelixis Inc | Composiciones farmacéuticas moduladoras de c-Met |
EP2593091A1 (en) | 2010-07-16 | 2013-05-22 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
US20140066444A1 (en) | 2010-09-27 | 2014-03-06 | Exelixis, Inc. | Method of Treating Cancer |
JP2013543011A (ja) | 2010-11-22 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 癌の治療法 |
TW201309650A (zh) | 2011-02-10 | 2013-03-01 | Exelixis Inc | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
UA115866C2 (uk) | 2011-09-22 | 2018-01-10 | Екселіксіс, Інк. | Спосіб лікування остеопорозу |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
WO2013070890A1 (en) | 2011-11-08 | 2013-05-16 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
ES2726605T3 (es) | 2012-09-07 | 2019-10-08 | Exelixis Inc | Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón |
US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
NZ712330A (en) | 2013-03-15 | 2020-04-24 | Exelixis Inc | Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
MX2015014046A (es) | 2013-04-04 | 2016-05-16 | Exelixis Inc | Combinaciones de farmacos para tratar cancer. |
EP3119476A1 (en) | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
-
2012
- 2012-02-10 TW TW101104440A patent/TW201309650A/zh unknown
- 2012-02-10 BR BR112013020362A patent/BR112013020362A2/pt not_active Application Discontinuation
- 2012-02-10 MX MX2013009116A patent/MX2013009116A/es unknown
- 2012-02-10 AU AU2012214322A patent/AU2012214322B2/en active Active
- 2012-02-10 DK DK12704492.3T patent/DK2673262T3/da active
- 2012-02-10 US US13/984,559 patent/US9717720B2/en active Active
- 2012-02-10 WO PCT/US2012/024591 patent/WO2012109510A1/en active Application Filing
- 2012-02-10 AR ARP120100446A patent/AR085155A1/es not_active Application Discontinuation
- 2012-02-10 ES ES12704492T patent/ES2905571T3/es active Active
- 2012-02-10 GE GEAP201213221A patent/GEP20217235B/en unknown
- 2012-02-10 CN CN201280017723.1A patent/CN103459373B/zh active Active
- 2012-02-10 EA EA201391145A patent/EA033513B1/ru not_active IP Right Cessation
- 2012-02-10 PT PT127044923T patent/PT2673262T/pt unknown
- 2012-02-10 KR KR1020197012256A patent/KR20190049907A/ko active Application Filing
- 2012-02-10 TW TW105117666A patent/TWI640509B/zh active
- 2012-02-10 KR KR1020217002055A patent/KR20210010671A/ko not_active Application Discontinuation
- 2012-02-10 KR KR1020137023174A patent/KR102030447B1/ko active IP Right Review Request
- 2012-02-10 JP JP2013553580A patent/JP2014505109A/ja active Pending
- 2012-02-10 CA CA2826751A patent/CA2826751C/en active Active
- 2012-02-10 EP EP12704492.3A patent/EP2673262B1/en not_active Revoked
- 2012-02-10 HU HUE12704492A patent/HUE057574T2/hu unknown
- 2012-02-10 PL PL12704492T patent/PL2673262T3/pl unknown
- 2012-02-10 KR KR1020217038913A patent/KR20210147117A/ko not_active Application Discontinuation
- 2012-02-10 KR KR1020207007647A patent/KR20200031711A/ko active Application Filing
- 2012-02-10 EP EP21205831.7A patent/EP4019498A1/en active Pending
- 2012-02-10 KR KR1020237038819A patent/KR20230158644A/ko not_active Application Discontinuation
-
2013
- 2013-08-07 IL IL227848A patent/IL227848B/en active IP Right Grant
- 2013-08-13 ZA ZA2013/06072A patent/ZA201306072B/en unknown
-
2016
- 2016-05-10 JP JP2016094411A patent/JP6513598B2/ja active Active
- 2016-11-10 US US15/348,716 patent/US10123999B2/en active Active
-
2017
- 2017-07-14 AU AU2017204877A patent/AU2017204877A1/en not_active Abandoned
-
2018
- 2018-10-04 US US16/151,653 patent/US10543206B2/en active Active
-
2019
- 2019-05-29 AU AU2019203745A patent/AU2019203745B2/en active Active
- 2019-12-06 US US16/706,323 patent/US20200108059A1/en not_active Abandoned
-
2020
- 2020-11-19 AU AU2020273307A patent/AU2020273307A1/en not_active Abandoned
-
2021
- 2021-01-19 US US17/152,394 patent/US20210154185A1/en not_active Abandoned
- 2021-02-08 US US17/170,275 patent/US11298349B2/en active Active
- 2021-10-08 US US17/497,201 patent/US20220023284A1/en not_active Abandoned
-
2022
- 2022-02-24 US US17/679,634 patent/US20220175757A1/en not_active Abandoned
- 2022-10-06 AU AU2022246429A patent/AU2022246429A1/en active Pending
-
2024
- 2024-02-08 US US18/436,836 patent/US20240189298A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201306072B (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
HK1211209A1 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
IL233663B (en) | Indolysine compounds, processes for their preparation and pharmaceutical preparations containing them | |
IL235826A (en) | Diazaspirocycloalkanes and thenaspirocycloalkanes and their preparation | |
AP3864A (en) | Pharmaceutical composition | |
GB201118232D0 (en) | Pharmaceutical composition | |
EP2742941A4 (en) | PHARMACEUTICAL COMPOSITION WITH A DIAMIDE DERIVATIVE | |
HK1203815A1 (en) | Pharmaceutical compositions and methods for their preparation | |
HRP20180567T1 (hr) | Farmaceutski pripravak omeprazola | |
HK1214160A1 (zh) | 抑制劑的藥物組合物 | |
HK1189158A1 (en) | Pharmaceutical composition | |
HK1210710A1 (en) | Pharmaceutical composition comprising rebamipide | |
HRP20160901T1 (hr) | Farmaceutski pripravak koji sadrži solifenacin | |
IL235805A (en) | Pyrimidinyl-Diazaspiro compound and process for preparation | |
ZA201409039B (en) | Pharmaceutical compositions containing oligomeric lactic acid | |
AP2012006645A0 (en) | Pharmaceutical compositions comprising paracetamoland process for preparing the same | |
EP2727593A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL | |
SI2638894T1 (sl) | Farmacevtski sestavek, ki vsebuje fosfolipid | |
EP2711010A4 (en) | PHARMACEUTICAL COMPOSITION | |
SI2497774T1 (sl) | Derivati dihidrooksazolobenzodiazepinona, postopki za njihovo pripravo in farmacevtski sestavki, ki te spojine vsebujejo | |
EP2677868A4 (en) | PHARMACEUTICAL COMPOSITIONS OF MARAVIROC AND METHOD OF PREPARING THEM | |
ZA201309537B (en) | Pharmaceutical composition comprising fexofedine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J204 | Request for invalidation trial [patent] | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2022100001249; TRIAL DECISION FOR INVALIDATION REQUESTED 20220427 Effective date: 20230428 |